<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>ISRG on Deep Analyst AI</title><link>https://deepanalyst.ai/tags/ISRG/</link><description>Recent content in ISRG on Deep Analyst AI</description><generator>Hugo -- gohugo.io</generator><language>en-us</language><lastBuildDate>Sat, 21 Feb 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://deepanalyst.ai/tags/ISRG/rss.xml" rel="self" type="application/rss+xml"/><item><title>Forget the Skinny-Jab Apocalypse: Why Intuitive Surgical is Eating Ozempic for Lunch</title><link>https://deepanalyst.ai/posts/2026/02/isrg-forget-skinny-jab-apocalypse-why-intuitive-surgical-is-eating-ozempic-lunch/</link><pubDate>Sat, 21 Feb 2026 00:00:00 +0000</pubDate><guid>https://deepanalyst.ai/posts/2026/02/isrg-forget-skinny-jab-apocalypse-why-intuitive-surgical-is-eating-ozempic-lunch/</guid><description>Forget the Skinny-Jab Apocalypse: Why Intuitive Surgical is Eating Ozempic for Lunch Wall Street has been reacting to the GLP-1 weight-loss craze like a teenager discovering nihilism—suddenly convinced nothing else matters. The prevailing, breathless narrative claimed Ozempic would render bariatric surgery obsolete, leaving Intuitive Surgical (ISRG) and its expensive droids to rust in hospital basements. But while the algos hyperventilated over shrinking waistlines, they ignored a critical reality: the robot doesn&amp;rsquo;t care if you&amp;rsquo;re skinny.</description></item></channel></rss>